UK regulator suspends Amgen’s Tavneos for new patients
Britain’s medicines regulator suspended the use and sale of Amgen’s rare-disease drug Tavneos to new patients, saying the main study supporting its approval was unreliable.
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's NASDAQ:AMGN rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.